t20

Dextran T20 (MW 20,000) is a polymer of dehydrated glucose with an average molecular weight of 20,000. It exhibits excellent biodegradability and biocompatibility, making it suitable for use in food, pharmaceuticals, cosmetics, and research fields.

Enfuvirtide is an anti-HIV-1 fusion peptide that inhibits HIV p24 antigen and Gag gene expression in macrophages.

Enfuvirtide acetate salt is a linear synthetic peptide made of 36 amino acids. It has an acetylated N-terminus and a carboxamide C-terminus.

T20-M is a precursor peptide with strong binding affinity for UBE2C.

KT203, a selective and potent structural domain 6 (ABHD6) inhibitor of alpha/beta hydrolytic enzymes, exhibits potential antiviral and anti-inflammatory properties for pneumonia research.

DT204 is an SCFSkp2 inhibitor that reduces the binding of Skp2 to Cullin-1 and Commd1. It can be used to study multiple myeloma.

TTT20171 is an SDHC inhibitor that demonstrates nanomolar-level inhibition of CII; however, it shows limited efficacy within cellular environments. In cell assays, the most responsive cells, 22Rv1 prostate cancer cells, exhibit an IC50 of 5.4 µM, which significantly exceeds both the suggested usage concentration of 2 µM and the chemical probe quality standard of 1 µM.

PNT2001 (LY4181530) is an effective prostate-specific membrane antigen (PSMA) ligand with an IC50 of 3.1 nM. It enhances cellular internalization and, when labeled with 177Lu and 225Ac, is applicable for prostate cancer research.

YLT205 is an inducer of apoptosis in human colorectal cells that acts by inhibiting tumor growth.

FT206 is a carboxamide inhibitor of ubiquitin-specific protease[1].

NPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. NPT200-11 can be used in studies about the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA).

MT204 is a humanized IgG1 antibody inhibitor that targets IL-2 from human and rhesus monkey sources. It prevents soluble IL-2 from binding to the intermediate-affinity IL-2 receptor and blocks IL-2 bound to CD25 from interacting with the high-affinity IL-2 receptor. In rhesus monkey allogeneic skin transplant models, MT204 shows excellent tolerability and potent immunosuppressive activity. With linear pharmacokinetics, a reasonable serum half-life, and signs of good safety and efficacy, MT204 holds promise for use in immunotherapy.

SCT200 is a fully humanized IgG1 monoclonal antibody targeting EGFR, with a Kd value of 0.08 nM. It can eliminate tumor cells via complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through its Fc fragment. SCT200 is utilized in research on refractory RAS and BRAF wild-type metastatic colorectal cancer.

CT20p is an anticancer peptide derived from the hydrophobic terminal of BaxC. It exhibits a unique cytotoxic effect independent of the full-length Bax, targeting mitochondria to induce fusion-like aggregation and mitochondrial membrane hyperpolarization. CT20p reduces α5β1 integrin levels, inhibits F-actin polymerization, thus disrupting the cytoskeleton and preventing cell adhesion. CT20p is applicable in breast cancer research.

Dextran T200 (MW 200,000) is a polymer of dehydrated glucose with an average molecular weight of 200,000. It has excellent biodegradability and biocompatibility, making it suitable for use in the fields of food, pharmaceuticals, cosmetics, and research.

LY294002 (SF 1101) is a broad-spectrum inhibitor of PI3K, inhibiting PI3Kα, PI3Kδ, and PI3Kβ (IC50=0.5/0.57/0.97 μM). LY294002 is also an inhibitor of DNA-PK (IC50=1.4 μM) and an inhibitor of CK2 (IC50=98 nM). LY294002 activates apoptosis and autophagy.

PF-573228 is an ATP-competitive FAK inhibitor. In a cell-free assay, the IC50 of FAK is 4 nM.

ATP (Adenosine triphosphate) provides cellular energy, participates in overall energy balance, and maintains intracellular homeostasis. ATP can act as an extracellular signaling molecule through interactions with specific purinergic receptors to mediate a variety of processes including neurotransmission, inflammation, apoptosis, and bone remodeling.

AK-1690 is a potent and selective STAT6 PROTAC degrader that induces degradation of STAT6 proteins in cells (DC50=1 nM) and depletes STAT6 proteins in mouse tissues, which can be used in cancer research.

NNK is a nitrosated derivative of nicotine that activates the ERK1/2 and PKCα signaling pathways, induces Bcl2 phosphorylation at Ser70, and activates c-Myc at Thr58 and Ser62, thereby promoting the proliferation and survival of human lung cancer cells, and is commonly used to establish lung cancer mouse models.

Semaxinib (SU5416) is a potent and selective VEGFR2 inhibitor (IC50: 1.23 μM), exhibiting a 20-fold greater selectivity for VEGFR2 over PDGFRβ, with no activity against InsR, EGFR, and FGFR. Semaxinib reversibly inhibits ATP binding to the tyrosine kinase domain of VEGFR2, potentially inhibiting VEGF-stimulated endothelial cell migration and proliferation, thereby reducing tumor microvasculature.

Quizartinib (AC220) is an inhibitor of FLT3 (Kd: 1.6 nM) and demonstrates high selectivity for FLT3 when tested against a panel of 227 additional kinases.

ABT-737 is a BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w (EC50=30.3 nM/78.7 nM/197.8 nM). ABT-737 exhibits antitumor activity and anti-aging activity.

Talazoparib (LT-673) is a new-type PARP inhibitor (IC50: 0.58 nM), It similarly binds to PARP1/2 (Kis: 1.2/0.85 nM).